Enrollment of Females in Randomized Trials for Glucagon-Like Peptide 1 Receptor Agonists
Open Access
- 8 November 2024
- journal article
- Published by Elsevier in JACC: Advances
- Vol. 3 (12) , 101386
Abstract
No abstract availableKeywords
This publication has 53 references indexed in Scilit:
- Cardiovascular and renal outcomes of glucagon-like peptide 1 receptor agonists among patients with and without type 2 diabetes mellitus: A meta-analysis of randomized placebo-controlled trialsAmerican Journal of Preventive Cardiology, 2024
- Exclusion of Women from Phase I Trials: Perspectives from Investigators and Research Oversight OfficialsEthics & Human Research, 2023
- Racial, Ethnic, and Socioeconomic Inequities in Glucagon-Like Peptide-1 Receptor Agonist Use Among Patients With Diabetes in the USJAMA Health Forum, 2021
- Improving the enrollment of women and racially/ethnically diverse populations in cardiovascular clinical trials: An ASPC practice statementAmerican Journal of Preventive Cardiology, 2021
- Trial characteristics associated with under‐enrolment of females in randomized controlled trials of heart failure with reduced ejection fraction: a systematic reviewEuropean Journal of Heart Failure, 2020
- Enrollment of Older Patients, Women, and Racial and Ethnic Minorities in Contemporary Heart Failure Clinical TrialsJAMA Cardiology, 2018
- The Impact of Cardiovascular Disease Prevalence on Women's Enrollment in Landmark Randomized Cardiovascular Trials: A Systematic ReviewJournal of General Internal Medicine, 2011
- Sex Differences in Perceived Risks, Distrust, and Willingness to Participate in Clinical TrialsArchives of internal medicine (1960), 2007
- Sex and Gender Factors in Medical StudiesJAMA, 2003
- Representation of the Elderly, Women, and Minorities in Heart Failure Clinical TrialsArchives of internal medicine (1960), 2002